Article
Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
Frontiers in immunology - 1 Jan 2023
Li Yujing, Jiang Haohua, Qian Fangfei, Chen Ya, Zhou Wensheng, Zhang Yanwei, Lu Jun, Lou Yuqing, Han Baohui, Zhang Wei
Abstract excerpt
Introduction: Platinum-based chemotherapy is still the standard of care for Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients after developing EGFR-TKI resistance. However, no study focusing on the role of immuno checkpoint inhibitor (ICI) based treatments for EGFR mutated NSCLC patients who carried programmed death ligand 1 (PD-L1) tumor proportion score (TPS) greater...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.